To assess the therapeutic potential of dual PD-L1 and CD47 inhibition in HCC, we established subcutaneous Hepa 1–6 tumors in mice and treated them with anti-PD-L1 aptamer, CD47 siRNA and PD-L1 × CD47 siRNA chimera (2 mg/kg, every 3 days from day 7 to 29) (Fig. 3a-b). This evidence concerns the gene CD47 and hepatocellular carcinoma.